BAY2599023 (DTX201) clinical trials

Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"

This study is testing a new gene therapy called BAY 2599023 (DTX201) for men with severe haemophilia A. It aims to help their bodies make the missing clotting factor VIII by introducing a healthy gene, potentially reducing bleeding episodes.